We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Pfizer’s new $35 million clinical research unit (CRU) in New Haven, Conn., will be used to confirm the safety and action of potential new drugs in Phase I trial volunteers.
The number of new molecular entities (NMEs) approved by the FDA has increased in recent years, but drug researchers believe it’s getting harder to develop drugs and get approvals for their products, according to a new survey.
Spending growth for prescription drugs in the U.S. decelerated at a rapid rate in 2003, according to new data released by the Centers for Medicare & Medicaid Services (CMS).
Patent settlements between brand and generic drugmakers have increased in recent years, and the agreements are being completed without payments from the brand to the generic in exchange for the generic’s commitment not to market the product, according to a new federal study.
Drug giant Pfizer will provide up to $35 million worth of medicines and financial aid to help the victims of the recent earthquake and tsunami that have devastated countries in Asia and along the east coast of Africa.
The advent of the Medicare drug benefit in 2006 could force drugmakers to move more aggressively into developing drugs similar to those already found in therapeutic categories, says an industry expert.
Pharmaceutical R&D spending could plummet as much as 40 percent if the federal government were to leverage its buying power under the Medicare Modernization Act (MMA) to force down drug prices, according to a new study by a public policy think tank.
Janssen Pharmaceutica Products is sending “Dear Healthcare Professional” letters to more than 200,000 doctors and pharmacists in light of reports about errors in the prescribing and dispensing of the company’s Alzheimer’s drug, Reminyl.